For example, combined treatment with trametinib and sapanisertib in order to inhibit both MEK and mTOR pathways (Figure 3A) has been reported to induce apoptosis and reduce cell survival in canine melanoma cell lines (72), and one study reported that inhibition of the mTOR pathway reduced invasion and angiogenesis in hemangiosarcoma cell lines (125). Here, MTOR is linked to angiosarcoma.